Gland Pharma Wins USFDA Nod for Generic Depo-Medrol Injection
Gland Pharma wins USFDA approval for generic Methylprednisolone Acetate Injectable Suspension, equal to Pfizer’s Depo-Medrol, a USD 214 million US market.
Gland Pharma wins USFDA approval for generic Methylprednisolone Acetate Injectable Suspension, equal to Pfizer’s Depo-Medrol, a USD 214 million US market.
Senores Pharmaceuticals will expand capacity at its US subsidiary Havix from 1.2 billion to 2 billion units a year and at Apnar Pharma in India from 0.5 billion to 1.2 billion units, and add a 2.7 million-unit prefilled syringe line at Ratnatris, for an estimated ₹43 crore by March 2027.
Ahmedabad-based fermentation API maker Concord Biotech grew Q2 FY27 revenue 25% to ₹309.1 crore as API sales rose 30%, while solvent and power costs trimmed gross margin; the company added two US ANDA approvals, launched its Inspira dermatology division and is chasing injectables contracts.
Morepen Laboratories reported Q2 FY27 revenue of ₹755 crore, up 81%, and EBITDA of ₹132 crore, up 273%, as its CDMO business hit commercial scale, exports more than doubled and it filed its first US ANDA.